Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The passing of Her Majesty Queen Elizabeth II

The University of Oxford is deeply saddened to learn of the death of Her Majesty Queen Elizabeth II. The University enjoyed a close relationship with the Queen throughout her reign and gives thanks for her 70 years of service to the nation.

Malaria booster vaccine continues to meet WHO-specified 75% efficacy goal

Researchers from the University of Oxford and their partners have today reported new findings from their Phase 2b trial following the administration of a booster dose of the candidate malaria vaccine, R21/Matrix-M™ – which previously demonstrated high-level efficacy of 77% over the following 12 months in young west African children in 2021. In their findings (reported in The Lancet Infectious Diseases), they found that a vaccine booster dose at one year following a primary three-dose regime maintained high efficacy against malaria, and continued to meet the World Health Organization’s Malaria Vaccine Technology Roadmap goal of a vaccine with at least 75% efficacy.

More than 10 million children were affected by COVID-19-associated parental and caregiver deaths

According to a new modelling study, published in JAMA Pediatrics, the number of children estimated to have experienced the death of a parent or caregiver as a result of the COVID-19 pandemic has climbed to more than 10.5 million globally as of May 1, 2022.

Genetic mapping of tumours reveals how cancers grow

Researchers from the University of Oxford, KTH Royal Institute of Technology, Science for Life Laboratory, and the Karolinska Institutet, Solna, Sweden, have found that individual prostate tumours contain a previously unknown range of genetic variation.

Tackling suicide risk in people with mental disorders

Clinical researchers from Oxford University’s Department of Psychiatry and Oxford Health NHS Foundation Trust have developed guidance to help clinicians identify and treat patients at risk of suicide.

Antimicrobial resistant bacteria found in newborn children from low- and middle-income countries

Sepsis is a primary cause of mortality in newborns, particularly in low- and middle-income countries (LMICs). A new study coordinated by Professor Tim Walsh at the Ineos Oxford Institute for Antimicrobial Research (IOI) and Department of Biology looks at the links between the presence of bacteria resistant to antibiotics isolated from mothers and their newborn babies living across 7 LMICs in Africa and South Asia. They show that antimicrobial resistant bacteria are present in neonates after just a few hours of life, and find examples of transmission of sepsis-causing resistant bacteria within hospitals and from mothers to babies.

Viral role in Alzheimer's Disease discovered

Researchers from Oxford’s Institute of Population Ageing, Tufts University and the University of Manchester have discovered that common viruses appear to play a role in some cases of Alzheimer’s disease (AD).

Professor Hugh Watkins wins £30 million research award to cure killer heart diseases

The British Heart Foundation award aims to help researchers rewrite DNA, in “defining moment” for cardiovascular medicine.

Researchers develop new breath-driven concept set to transform access to hand prosthetics

The new air-powered hand provides a lightweight, low-maintenance and easy-to-use body-powered prosthetic option particularly well suited for children and those in low and middle-income countries.

New rabies vaccine candidate demonstrates promising immune response and safety

Researchers from the University of Oxford have today reported new findings from a Phase 1 clinical trial studying the immune response and safety of their newly-developed single shot rabies vaccine, ChAdOx2 RabG - with promising results identified.

Load More